Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

Summary

This is a prospective, single-arm, phase II study, and the purpose of this study is to evaluate the efficacy and safety of Pola-R2 regimen in newly diagnosed elderly diffuse large B cell lymphoma classified into un-fit or frail group by comprehensive geriatric assessment(CGA).

Eligibility

Inclusion Criteria:

* The patient volunteered to participate in the study and signed the Informed Consent
* Histopathologically confirmed DLBCL and treatment naive(corticosteroids alone is not considered as a line of treatment)
* Age≥ 70 years old, and was un-fit or frail according to comprehensive geriatric assessment
* Adequate organ function and adequate bone marrow reserve

Exclusion Criteria:

* Coexisting malignancy other than lymphoma
* Active HBV infection
* Any instability of systemic disease, including but not limited to active infection (except local infection), severe cardiac, liver, kidney, or metabolic disease need therapy

Conditions2

Browse More Trials